Androgen Deprivation Therapy is Inappropriate for Early-Stage or Localized Disease
the Cancer Therapy Advisor take:
In a study recently published in European Urology, researchers from the Henry Ford Hospital indicate that androgen deprivation therapy should not be used for men who have prostate cancer that has not spread beyond the prostate.
The researchers said that this message is especially relevant to men who are not considered to be high risk, because androgen deprivation therapy was show to expose patients to more side effects and was associated with an increased risk of death.
The research analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database between 1992 and 2009 and then found records from Medicare and linked 46,376 men diagnosed with localized prostate cancer who did not undergo radical prostatectomy or radiation therapy for prostate cancer. The researchers found that among those patients, 38.5% were treated with androgen deprivation therapy.
Androgen deprivation therapy is an injected or implanted medicine that interferes with the body’s typical testosterone creation process. The well established adverse events related to androgen deprivation therapy include weight gain, heart disease, impotence, and diabetes; mounting evidence suggests that androgen deprivation therapy is also linked to an increase in early death.
Although androgen deprivation therapy is still the standard of care for patients whose prostate disease has spread beyond the prostate, there is no evidence that it is a useful or effective treatment for early or localized disease.
ADT should not be used for men who have prostate cancer that has not spread beyond the prostate.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Larotrectinib Continues to Show Efficacy in TRK-Fusion Cancers
- First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
- Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
- Entrectinib Shrank NTRK Fusion-Positive Solid Tumors
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer